Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 10, 2022

SELL
$57.56 - $82.54 $418,058 - $599,488
-7,263 Closed
0 $0
Q4 2021

Feb 03, 2022

SELL
$72.5 - $100.68 $60,972 - $84,671
-841 Reduced 10.38%
7,263 $565,000
Q3 2021

Oct 27, 2021

BUY
$90.24 - $124.05 $6,497 - $8,931
72 Added 0.9%
8,104 $773,000
Q2 2021

Aug 16, 2021

BUY
$93.66 - $139.27 $21,354 - $31,753
228 Added 2.92%
8,032 $999,000
Q1 2021

May 14, 2021

SELL
$116.57 - $155.01 $27,393 - $36,427
-235 Reduced 2.92%
7,804 $1.03 Million
Q4 2020

Feb 09, 2021

SELL
$99.61 - $142.12 $20,320 - $28,992
-204 Reduced 2.47%
8,039 $1.07 Million
Q3 2020

Nov 12, 2020

BUY
$72.92 - $102.01 $285,992 - $400,083
3,922 Added 90.77%
8,243 $841,000
Q2 2020

Aug 12, 2020

SELL
$55.75 - $92.75 $75,485 - $125,583
-1,354 Reduced 23.86%
4,321 $376,000
Q1 2020

May 12, 2020

BUY
$37.9 - $104.44 $215,082 - $592,697
5,675 New
5,675 $329,000
Q4 2018

Feb 11, 2019

SELL
$56.04 - $82.66 $368,799 - $543,985
-6,581 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$48.29 - $80.6 $41,529 - $69,316
-860 Reduced 11.56%
6,581 $519,000
Q2 2018

Aug 07, 2018

BUY
$37.84 - $69.96 $281,567 - $520,572
7,441 New
7,441 $445,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $12.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Greenwood Capital Associates LLC Portfolio

Follow Greenwood Capital Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Greenwood Capital Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Greenwood Capital Associates LLC with notifications on news.